Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...
Dose-Response Relationship: Potency and Efficacy01:22

Dose-Response Relationship: Potency and Efficacy

The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it produces...
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Bioequivalence: Overview01:16

Bioequivalence: Overview

Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Persistent Frequent Emergency Department Use Before and During the COVID-19 Pandemic: A Longitudinal Study of One Million Users.

Medical care·2026
Same author

Increased formation of angiotensin II from angiotensin I in individuals of African descent.

Journal of hypertension·2025
Same author

Correction: Practice patterns on the management of secondary hyperparathyroidism in the United States: Results from a modified Delphi panel.

PloS one·2025
Same author

Practice patterns on the management of secondary hyperparathyroidism in the United States: Results from a modified Delphi panel.

PloS one·2025
Same author

Cost-Effectiveness of a Shock Team Approach in Refractory Cardiogenic Shock.

Circulation. Heart failure·2024
Same author

Economic Impact of Ambulatory Blood Pressure Monitoring Compared With Clinical Blood Pressure Monitoring: A Simulation Model.

Health services insights·2024

Related Experiment Videos

Statin cost-effectiveness comparisons using real-world effectiveness data: formulary implications.

Robert L Ohsfeldt1, Sanjay K Gandhi, Kathleen M Fox

  • 1Texas A&M Health Science Center, College Station, TX 77843-1266, USA. rohsfeldt@srph.tamhsc.edu

Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|May 21, 2008
PubMed
Summary

Rosuvastatin demonstrated superior effectiveness and cost-efficiency in lowering low-density lipoprotein cholesterol (LDL-C) compared to atorvastatin in clinical practice. Generic simvastatin requires significant discounts to match lovastatin

Related Experiment Videos

Area of Science:

  • Cardiovascular Medicine
  • Pharmacoeconomics
  • Clinical Pharmacy

Background:

  • Statins are crucial for managing hyperlipidemia and reducing cardiovascular risk.
  • Understanding the comparative effectiveness and cost-effectiveness of generic versus branded statins is vital for optimizing patient care and healthcare resource allocation.

Purpose of the Study:

  • To compare the effectiveness and cost-effectiveness of generic and branded statins in routine clinical practice.
  • To evaluate statin performance in reducing low-density lipoprotein cholesterol (LDL-C) and achieving target LDL-C levels.

Main Methods:

  • Retrospective analysis of a large patient database (10,421 individuals aged 18+).
  • Newly prescribed statin therapy was assessed for effectiveness in LDL-C reduction and goal attainment.
  • Cost-effectiveness was evaluated based on LDL-C lowering and goal achievement.

Main Results:

  • Rosuvastatin achieved significantly greater LDL-C reduction (-31.6%) compared to other statins (-13.9% to -21.9%).
  • Higher percentage of moderate/high-risk patients attained LDL-C goals with rosuvastatin (76.1%) versus other statins (57.6-72.6%).
  • Rosuvastatin was more effective and less costly than atorvastatin; simvastatin required >61% discount to match generic lovastatin's cost-effectiveness.

Conclusions:

  • Rosuvastatin is more effective and cost-efficient for lowering LDL-C and achieving lipid goals than atorvastatin in clinical practice.
  • Simvastatin's cost-effectiveness is comparable to lovastatin only with substantial discounts off its branded price.